Vol. 23 - Num. 91
Evidence based Pediatrics
aServicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
bServicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: C Ochoa. E-mail: email@example.com
Reference of this article: Ochoa Sangrador C, Gimeno Díaz de Atauri Á. Bronchodilators in bronchiolitis: should we reassess their selective use? Rev Pediatr Aten Primaria. 2021;23:317-20.
Published in Internet: 20-09-2021 - Visits: 1215
Authors’ conclusions: compared to guidelines‐guided strategy, treating infants with viral bronchiolitis using the phenotypic‐guided bronchodilator therapy strategy is a more cost‐effective strategy, because it involves a lower probability of hospital admission at lower total treatment costs. Randomized controlled trials using biomarkers to stratify patients most likely to respond to bronchodilators are necessary.
Reviewers’ commentary: the available information does not seem sufficient to make changes to the current recommendations in acute bronchiolitis management. There is still need for a predictive model that allows to identify potential responders to bronchodilators, as well as a clinical trial with a sufficient sample size to estimate the effectiveness of the strategy of its selective use.
Keywords● Bronchiolitis ● Bronchodilators ● Costs and cost analysis.
This article has no comments yet.